Zhifei Unit's Nasal Spray RSV Vaccine Trial Application Accepted by NMPA
Zhifei Biological announced on August 10 that its wholly-owned subsidiary Zhifei Luzhu has received a clinical trial application acceptance notice from the National Medical Products Administration for a nasal spray recombinant respiratory syncytial virus (RSV) vaccine using a chimpanzee adenovirus vector. The vaccine is administered via nasal spray and targets the prevention of respiratory syncytial virus infection.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 50/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.